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Purpose: To determine the predictors of success for adjuvant selective laser trabeculoplasty 
(SLT) in Chinese primary open angle glaucoma (POAG) patients. 
Methods: This prospective study recruited Chinese subjects with unilateral or bilateral POAG 
currently taking medication to reduce intraocular pressure (IOP). All subjects received a single 
session of 360° SLT treatment and continued their medications for 1 month. SLT success was 
defined as IOP reduction 20% at 1 month. The following covariates were analyzed in both 
groups via univariate and multivariate analyses: age, sex, lens status, initial IOPs, post-SLT 
IOPs, number and type of medications, SLT shots and energy, and pre-SLT investigations.
Results: In 51 eyes of 33 POAG subjects, the success rate of SLT was 47.1%. Certain groups 
of patients were associated with greater success using univariate analysis. These groups 
included the following: older age (coefficient =0.1; OR: 1.1; P=0.0003), a higher pre-SLT IOP 
(coefficient =0.3; OR: 1.3; P=0.0005), using four types of antiglaucoma medication (coeffi-
cient =2.1; OR: 8.4; P=0.005), a greater degree of spherical equivalent (coefficient =2.1; OR: 
8.4; P=0.005), and the use of a topical carbonic anhydrase inhibitor (coefficient =1.7; OR: 6.0; 
P=0.003). None of the covariates were significant using multivariate analysis. 
Conclusion: Older age, a higher pretreatment IOP, using multiple antiglaucoma medications 
especially topical carbonic anhydrase inhibitor, and higher refractive errors were associated 
with greater SLT success. 
Keywords: primary open angle glaucoma, selective laser trabeculoplasty, intraocular pressure, 
success, Chinese
Introduction
Selective laser trabeculoplasty (SLT) is an increasingly popular treatment for primary 
open angle glaucoma (POAG) because it is a simple office procedure that is effective 
and repeatable, with minimal downtime and few long-term side effects.1 However, 
some of biggest challenges of using SLT are in predicting which patients will respond, 
by how much, and for how long. The response rate ranges from 59% to 96%, and 
the amount of intraocular pressure (IOP) reduction ranges from 18% to 40% over a 
6–12 month period.1 Previously, factors that have been consistently reported to predict 
SLT success throughout the literature include no prior antiglaucoma medication use1–3 
and a higher IOP before SLT.4 There is limited information in the literature investi-
gating the predictors for SLT success in the Chinese population. Differences in angle 
pigmentation may affect the outcome of SLT,5 making predictive factors different in 
this population from Western counterparts. The aim of this study is to determine the 
predictors of adjuvant SLT success in a Chinese POAG population. 
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Methods
This prospective cohort study sequentially recruited  Chinese 
subjects from the ophthalmology clinic of a university 
hospital, Queen Mary Hospital, Hong Kong, Special 
Administrative Region, People’s Republic of China, from 
September 2011 to September 2012. The study included 
subjects with POAG currently on antiglaucoma medica-
tion. SLT was offered as adjuvant therapy to these patients 
either to reduce polypharmacy or to achieve a lower target 
IOP based on their individual clinical needs. Subjects were 
excluded if they had preexisting corneal pathology or scars, 
previous argon laser trabeculoplasty or SLT treatment, or 
if they did not comply with follow-up visit requirements. 
There was no washout prior to SLT. A single session of 
SLT was performed by a single surgeon (JWYL) using a 
Q-switched neodymium-doped yttrium aluminium garnet 
(Nd:YAG) laser (Ellex Solo™; Ellex Medical Pty. Ltd., 
Adelaide, Australia), for 360° in all patients with an initial 
energy of 0.8 mJ and titrated until bubble formation was 
just visible. For those with bilateral disease, both eyes were 
treated in the same laser session. In all treated eyes, a single 
drop of Alphagan® P (Allergan, Inc., Irvine, CA, USA) was 
instilled immediately after SLT. A dexamethasone 0.1% 
and Neomycin 0.5% combination eye drop (Dexoptic-N; 
Ashford Laboratories Pvt. Ltd., Mumbai, India) was used 
twice daily for 1 day and was continued for a few more 
days only if anterior chamber reaction was detected during 
follow-up. Patients returned for follow-up visits on day 1 
and 1 week, 1 month, and 3 months after SLT. Patients 
continued the same antiglaucoma drug regime for the first 
month after SLT. Medications were subsequently titrated 
to achieve individual target pressures based on clinical 
requirements.
The following parameters were recorded during the 
study: age, sex, lens status (phakic or pseudophakic), pre-
senting IOP without medication (obtained from medical 
records), pre-SLT IOP, post-SLT day 1 IOP, post-SLT 
1 week IOP, number of types of antiglaucoma medications, 
number of SLT shots, and average laser energy used. In 
addition, we measured pre-SLT average retinal nerve fiber 
layer (RNFL) via a Spectralis® optical coherence tomog-
raphy, pre-SLT visual field index (VFI) on a Humphrey 
Field Analyzer (Humphrey Instruments, Inc., San Leandro, 
CA, USA), pre-SLT endothelial cell count via a noncontact 
specular microscopy (Noncon ROBO-CA; Konan Medi-
cal USA Inc., Irvine, CA, USA), pre-SLT central corneal 
thickness via videokeratography (Orbscan® IIz; Bausch 
& Lomb Incorporated, Bridgewater, NJ, USA), pre-SLT 
Snellen visual acuity, and pre-SLT spherical equivalent via 
kerato-refractometer (Topcon KR-8900; Topcon Europe 
Medical B.V., Capelle aan den IJssel, the Netherlands). 
We recorded the type of antiglaucoma eye drops that patients 
used pre-SLT, including beta-blockers, carbonic anhydrase 
inhibitors, prostaglandin analogs, alpha agonists, or pilo-
carpine. All IOP readings were measured via Goldmann 
applanation tonometry by a single investigator, and trained 
optometrists measured all other ocular parameters. Subjects 
were asked to return for follow-up at approximately the 
same time intervals during the day to minimize the effect 
of diurnal IOP fluctuation.
This study adhered to the tenets of the Declaration of 
Helsinki. Informed patient consent and approval by the 
institutional review board were obtained prior to study com-
mencement. The authors declare no financial or proprietary 
interests. 
Definition of success
The definition of SLT success was determined as 20% 
IOP reduction at 1 month after SLT as compared to the 
pre-SLT IOP. The 1-month post-op IOP was selected for 
continuity since all antiglaucoma medications were kept 
unchanged until then. Antiglaucoma medications were 
titrated to achieve individual target pressures, so the IOPs 
measured beyond 1 month were not solely representative of 
the efficacy of SLT.
statistics
The association of the 24 covariates (Table 1) with SLT 
success was analyzed using univariate logistic analysis and 
multiple regression analysis. The high collinearity among the 
covariates hindered the interpretation of traditional multiple 
logistic regression. To overcome this, variable selection by 
elastic net approach was first conducted to remove redundant 
covariates where the estimates of coefficients equaled to zero 
prior to multiple regression analysis.
We performed both the univariate and multivariate 
regression analyses for the following three datasets sepa-
rately: 1) both eyes, 2) right eyes only, and 3) left eyes only. 
We found that the significant variables detected from the right 
and left eyes were different, signifying that each eye has a 
unique underlying distribution that was different from the fel-
low eye. Furthermore, the analysis using data from both eyes 
was more comprehensive in including all variables that were 
significant than using just the right or left eye alone. Hence, 
we adopted the methodology of including both eyes in the 
dataset as this revealed all the possible significant variables.
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Correlations were expressed in coefficients and odds ratio 
(OR), and a P0.05 was considered statistically significant. 
All means were expressed as the mean ± standard deviation. 
Results 
In 51 eyes of 33 subjects that were enrolled in the study, 
there were ten right eyes, five left eyes, and 18 subjects that 
received SLT bilaterally. The mean age was 62.4±11.5 years. 
The mean IOP at initial presentation prior to starting anti-
glaucoma medication was 24.6±3.3 mmHg with a pre-SLT 
IOP of 17.7±4.1 mmHg. Patients used 2.4±1.2 types of eye 
drops prior to SLT. The mean of the SLT shots applied was 
147.3±47.1 per session using a mean power of 1.0±0.1 mJ. 
The mean IOP at 1 month after SLT was 13.8±3.3 mmHg, 
representing a mean overall IOP reduction of 17.9%±20.0%. 
The success rate of SLT was 47.1% (24/51). 
Using univariate analysis, the following parameters 
were significantly associated with SLT success: older age 
(coefficient =0.1; OR: 1.1; P=0.0003), a higher pre-SLT 
IOP (coefficient =0.3; OR: 1.3; P=0.0005), using four types 
of antiglaucoma medication (coefficient =2.1; OR: 8.4; 
P=0.005), a higher spherical equivalent (coefficient =2.1; OR: 
8.4; P=0.005), and the use of a topical carbonic anhydrase 
inhibitor (coefficient =1.7; OR: 6.0; P=0.003). On multivari-
ate analysis, however, none of the covariates were found to 
influence SLT outcome significantly (Table 1).
Table 1 Univariate and multivariate regression analyses of the covariates affecting slT success in POag
Univariate logistic analysis  Multiple regression
P-value Coefficient 
estimates
Standard 
deviation
Odds 
ratio
P-value Coefficient 
estimates
Standard 
deviation
Odds 
ratio
age 0.0003* 0.11 0.04 1.11 0.18 0.38 0.28 1.46
sex 0.79 0.15 0.57 1.17 0.15 3.73 2.56 41.59
Pseudophakic 0.53 -0.56 0.92 0.57 0.20 -7.49 5.83 0.00
Phakic 0.83 -0.12 0.57 0.89 0.66 1.11 2.51 3.05
Presenting iOP (without 
medication)
0.80 -0.02 0.06 0.98 0.28 -0.39 0.36 0.68
Pre-slT iOP 0.0005* 0.28 0.09 1.32 0.11 1.10 0.69 3.01
Day 1 iOP post-slT 0.60 0.05 0.10 1.05 0.32 -0.62 0.63 0.54
1 week iOP post-slT 0.56 0.05 0.08 1.05 0.41 0.40 0.48 1.49
1 type of antiglaucoma 
medication
0.64 -0.29 0.62 0.75 0.30 4.28 4.11 72.37
2 type of antiglaucoma 
medication
0.17 -0.98 0.75 0.38 0.36 -3.35 3.67 0.04
3 type of antiglaucoma 
medication
0.58 -0.36 0.66 0.69 excluded from multivariate logistic analysis
4 type of antiglaucoma 
medication
0.005* 2.12 0.85 8.36 excluded from multivariate logistic analysis
slT shots 0.38 0.01 0.01 1.01 0.99 0.00 0.16 1.00
slT energy 0.37 0.01 0.01 1.01 0.94 0.01 0.16 1.01
Pre-slT rnFl 0.18 -0.02 0.02 0.98 0.96 0.00 0.06 1.00
Pre-slT VFi on hVF 0.09 -0.02 0.01 0.98 0.24 -0.09 0.07 0.92
Pre-slT endothelial cell 
count
0.90 0.00 0.00 1.00 0.16 0.00 0.00 1.00
Pre-slT central corneal 
thickness
0.54 0.00 0.01 1.00 0.18 -0.05 0.04 0.95
Pre-slT snellen Va 0.95 -0.08 1.35 0.92 0.93 0.51 5.98 1.67
Pre-slT spherical 
equivalent
0.02* 0.18 0.09 1.19 0.50 0.20 0.30 1.22
Pre-slT use of 
prostaglandin analogs
0.02 1.61 0.73 5.00 excluded from multivariate logistic analysis
Pre-slT use of 
β-blockers
0.22 0.81 0.68 2.25 excluded from multivariate logistic analysis
Pre-slT use of carbonic 
anhydrase inhibitors
0.003* 1.79 0.62 5.98 excluded from multivariate logistic analysis
Pre-slT use of α agonist 0.63 0.29 0.61 1.33 excluded from multivariate logistic analysis
Note: *Statistically significant.
Abbreviations: HVF, Humphrey visual field; IOP, intraocular pressure; POAG, primary open angle glaucoma; RNFL, retinal nerve fiber layer; SLT, selective laser 
trabeculoplasty; VA, visual acuity; VFI, visual field index.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
39
 o
n 
22
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1790
lee et al
Discussion 
In our population of medically treated Chinese POAG 
patients, a single session of adjuvant SLT achieved a mean 
IOP reduction of 18% with a response rate of 47%. These 
results are slightly lower than the previously published IOP 
reduction range of 18% to 40% and success rate range of 
59% to 96%.1 We postulate that these differences are likely 
attributed to the fact that the pre-SLT IOP in our population 
was medically controlled with topical antiglaucoma medica-
tion prior to SLT (17.7±4.1 mmHg while on 2.4±1.2 types 
of antiglaucoma eye drops). SLT was offered as adjuvant 
therapy to these patients either to reduce polypharmacy or 
to achieve a lower target IOP based on their individual clini-
cal needs. We demonstrated that a higher pre-SLT IOP was 
associated with greater SLT success (OR: 1.32; P=0.0005). 
This finding was consistent with what has been previously 
reported for the Western population.4,6,7
The use of four types of antiglaucoma medications 
(OR: 8.36; P=0.005) and the prior use of a topical carbonic 
anhydrase inhibitor (OR: 5.98; P=0.003) were associated 
with greater SLT success. Those who required four types 
of antiglaucoma medication were more likely to have a 
higher pre-SLT IOP (hence necessitating more antiglaucoma 
medication). Therefore, this may be an indirect effect from 
a higher pre-SLT IOP. As for the type of antiglaucoma 
medication used, previous reports have demonstrated that 
prostaglandin eye drops can potentially hinder the effects of 
SLT.4 The positive association of carbonic anhydrase inhibi-
tor use with SLT success has not been reported before. We 
postulate that it may not be the direct use of a topical carbonic 
anhydrase inhibitor that enhances SLT success but perhaps 
the use of this drug in place of a prostaglandin that accounts 
for this phenomenon, since prostaglandins can potentially 
counteract the action of metalloproteinase and macrophages 
in the trabecular meshwork following SLT.4 
Older age was found to be a significant predictor for suc-
cess (OR: 1.11; P=0.0003). This is contrary to the majority 
of reports in the literature that have found no significant 
association between age and SLT success.8–10 Our finding was 
in agreement with that of Ahmed et al who also reported that 
age 60 years was associated with greater success.11
Having a greater degree of spherical equivalent or more 
refractive error was also a predictor of SLT success (OR: 1.19; 
P=0.02). This association has not been reported before in the 
literature. This observation may be related to the association 
of myopia with POAG and the greater prevalence of myopia 
in our population compared to the Caucasian population.12,13 
We postulate that those with more refractive errors (most 
likely myopia since the mean spherical equivalent in our 
population was -3.54±4.05 diopters) were more likely to 
have deeper anterior chamber angles and theoretically, more 
areas of trabecular meshwork that were open and visible for 
treatment. While angle status was not found to influence 
SLT success in the Western population where an open angle 
configuration is the norm,14 this situation may be different in a 
Chinese population with a higher prevalence of anatomically 
narrower angles.15 Thus, those with a deeper anterior chamber 
may have better trabecular meshwork exposure for SLT, as 
it has been reported that treatment to 360° of the trabecular 
meshwork is far more superior to 180° treatment, which in 
turn is still more superior to only 90° of angle treatment.16
Our study had its limitations. Firstly, the 1-month IOP 
was used for the calculation of IOP response. A longer period 
following SLT would have been more ideal, but the deci-
sion was based on the following rationale: 1) patients were 
maintained on the same antiglaucoma medication regimen 
up to 1 month after SLT, hence the changes in IOP during 
this time would solely represent the effect of SLT, and 
2) based on previous reports in the literature, the IOP-low-
ering effects of SLT at 2 weeks was predictive of the IOP 
results at 3 months after laser.17 
Secondly, topical antiglaucoma medications were not 
washed out prior to SLT. The investigators felt that it would 
be unethical to stop antiglaucoma medication in the POAG 
group prior to laser as this would result in certain patients 
having a period of elevated IOP without medication. This 
decision was also based on previous reports in the literature 
confirming that eye drops use did not seem to influence SLT 
success significantly.6
Conclusion
Nevertheless, this is one of the few studies in the literature 
reporting the predictors of SLT success for a Chinese POAG 
population. It is also one of the first to report a positive 
association between SLT and the use of carbonic anhydrase 
inhibitor or a greater degree of spherical equivalent. In sum-
mary, SLT was successful in close to 50% of a sample of 
Chinese POAG patients. A higher pre-SLT IOP, using four 
types of antiglaucoma eye drops, use of a topical carbonic 
anhydrase inhibitor, older age, and higher refractive errors 
were predictors for SLT success.
Disclosure
The article processing charge was funded by Ellex Medical 
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